-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $104

Benzinga·08/11/2026 16:44:39
Listen to the news
B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $101 to $104.